US pharma shake-up: Trump announces steep tariffs on imported generic medicines

Donald Trump has announced a phased tariff plan for imported generic medicines, with duties rising to 100% and later 200%, potentially impacting global pharmaceutical exporters

PGurus Newsdesk

July 22, 2026

Donald Trump has announced a phased tariff plan on imported generic medicines, with duties rising to 100% and eventually 200% after a two-year grace period

US will keep generic drug imports tariff-free for two years before introducing steep import duties under President Trump’s new pharmaceutical trade policy

US President Donald Trump has announced a sweeping new tariff policy for imported generic medicines, setting the stage for a major shift in the global pharmaceutical industry while giving manufacturers a limited window to relocate production to the United States.

Under the new plan, imported generic drugs will continue to enter the US without tariffs for the next two years, beginning August 1. After the grace period ends, imports will attract a 100% tariff for one year, followed by a 200% tariff thereafter.

Trump said the phased approach is intended to encourage pharmaceutical companies to establish manufacturing facilities in the US rather than rely on overseas production. The administration argues that reshoring drug manufacturing will strengthen supply chain resilience and reduce America’s dependence on foreign suppliers.

The announcement has raised concerns among major generic drug exporters, particularly India, which is one of the largest suppliers of affordable medicines to the US market. Industry experts say the two-year tariff-free period provides companies with time to reassess manufacturing strategies, investment plans and supply chains before the higher duties take effect.

Markets reacted swiftly to the announcement, with pharmaceutical stocks coming under pressure amid concerns that higher US import duties could affect export competitiveness and future earnings.

While the policy is designed to boost domestic manufacturing, analysts warn it could also lead to higher drug costs and supply-chain disruptions if production does not shift quickly enough to the United States. The proposal is expected to remain closely watched by global pharmaceutical companies and exporting nations over the coming months.

For all the latest updates, download PGurus App.